Overview

• Phase II data from 149 patients showed trontinemab cleared amyloid plaques in over 90% of participants within 28 weeks
• Fewer than 5% of participants experienced amyloid-related imaging abnormalities and all cases resolved quickly
• An 18-month, 1,600-patient phase III trial has commenced to determine if plaque clearance yields memory and functional benefits
• Parallel prevention studies are evaluating trontinemab’s ability to ward off Alzheimer’s in asymptomatic individuals
• Engineered to cross the blood-brain barrier at low doses, trontinemab requires fewer infusions and less monitoring, although an earlier fatal brain hemorrhage underscores ongoing safety oversight